alexa Future Medicine for Todays Cancer Patients: Therapeutic Application of Pharmacogenomics in Oncology

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Future Medicine for Todays Cancer Patients: Therapeutic Application of Pharmacogenomics in Oncology

TPMT: Thiopurine S-methyltransferase; UGT1A1: Uridine diphosphate Glucuronosyltransferase 1A1; K-RAS (v-Kiras2 Kirsten Rat Sarcoma viral oncogene homologue), BRAF: serine/ threonine-protein kinase B-Raf; ABL: Abelson; BCR: Breakpoint Cluster Region; Ph1: Philadelphia chromosome; c-KIT: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; DPD: Dihydropyrimidine Dehydrogenase; EGFR: Epidermal Growth Factor Receptor; 5-FU: 5-Fluorouracil; G6PDH: Glucose-6-Phosphate Dehydrogenase; HER: Human Epidermal Growth Factor Receptor; 6-MP: 6-Mercaptopurine; Ph1: Philadelphia; G6PD:Glucose-6- Phosphate Dehydrogenase.

Citation: Feng X, Mello RL, Listiawan M, Quadro R (2014) Future Medicine for Today’s Cancer Patients: Therapeutic Application of Pharmacogenomics in Oncology. J Pharma Care Health Sys 1:119. doi: 10.4172/2376-0419.1000119

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger